0.00Open0.00Pre Close0 Volume0 Open Interest18.00Strike Price0.00Turnover639.54%IV-60.00%PremiumJul 26, 2024Expiry Date6.75Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8227Delta0.0558Gamma1.58Leverage Ratio-0.3361Theta-0.0006Rho-1.30Eff Leverage0.0019Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet